NCT02436486View on ClinicalTrials.gov

Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 31, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

Placebo

Capsules, orally, single dose

DRUG

ldalopirdine 120 mg

Two 60 mg encapsulated film-coated tablets, orally, single dose

DRUG

Idalopirdine 360 mg

Four 90 mg encapsulated film-coated tablets, orally, single dose

DRUG

Moxifloxacin 400 mg

Encapsulated tablets, orally, single dose

Trial Locations (1)

Unknown

FR801, Rennes

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT02436486 - Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men | Biotech Hunter | Biotech Hunter